FAT LOSS
Retatrutide — next-generation triple agonist
Also known as: Reta, LY-3437943, Triple-G agonistas
Retatrutide (LY-3437943) is Eli Lilly's investigational triple agonist activating GLP-1, GIP and glucagon receptors. Phase II trials showed an average 24.2% body weight reduction at 48 weeks — the highest figure ever recorded in pharmacological weight management.
Prices
How retatrutide works
By stimulating three receptors simultaneously, retatrutide combines appetite suppression (GLP-1), improved insulin sensitivity (GIP) and increased energy expenditure (glucagon). The glucagon component actively burns fat rather than only reducing intake.
Clinical data
Phase II (NEJM 2023): 12 mg weekly produced 24.2% weight loss over 48 weeks, outperforming both tirzepatide (~22% in 72 weeks) and semaglutide (~15%). Phase III TRIUMPH program ongoing; FDA filing expected 2026–2027.
Purity and testing
All gFITpeps.lt retatrutide vials are >99% pure, third-party HPLC verified by Janoshik Labs. COA available on request. Lyophilized form stable for 24 months at 2–8°C.
Frequently asked questions
Where can I buy retatrutide in Europe?
gFITpeps.lt ships research-grade retatrutide across the EU with 1–3 day delivery from Lithuania.
Is retatrutide stronger than tirzepatide?
Phase II data suggests yes — ~24% vs ~22% weight loss — thanks to the added glucagon receptor activity.
Research use only. Not for human consumption.